Showing results (181-190 of 432) with videos related to
Sort By:
Pageof 44
Clinical Epigenetics|September 22, 2016
Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomyMilan S Geybels, Jonathan L Wright, Marina Bibikova, et al.The Prostate|March 14, 2019
Clinical determinants for successful circulating tumor DNA analysis in prostate cancerMichael T Schweizer, Roman Gulati, Mallory Beightol, et al.Nature Cell Biology|April 12, 2022
Unchecked oxidative stress in skeletal muscle prevents outgrowth of disseminated tumour cellsSarah B Crist, Travis Nemkov, Ruth F Dumpit, et al.The Prostate|May 21, 2015
Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohortRohina Rubicz, Shanshan Zhao, Craig April, et al.Cell|September 3, 2013
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancerKai-Hsiung Chang, Rui Li, Barbara Kuri, et al.Oncotarget|May 12, 2016
A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicineEliezer M Van Allen, Dan Robinson, Colm Morrissey, et al.Cancer Cell|June 10, 2015
ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate TumorsLiem T Nguyen, Maria S Tretiakova, Mark R Silvis, et al.Cancer Research|August 27, 2011
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitorsChangmeng Cai, Sen Chen, Patrick Ng, et al.Biorxiv : the Preprint Server for Biology|January 7, 2025
Deciphering single-cell heterogeneity and cellular ecosystem dynamics during prostate cancer progressionFaming Zhao, Jianming Zeng, Canping Chen, et al.Biorxiv : the Preprint Server for Biology|June 12, 2025
Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancerNicole A Traphagen, Esmé Wheeler, Rong Li, et al.Pageof 44